NEXEL Co., Ltd. is a biotechnology company leading innovation in global non-clinical drug evaluation and New Approach Methodologies (NAMs), driven by human induced pluripotent stem cell (hiPSC) and AI convergence technologies.
NEXEL has established its proprietary core technology platform, TruDiSC (True Data generation from iPSCs for improving Synchrony with Clinical Data), delivering commercial-scale, high-quality hiPSC-derived cell and organoid products alongside precision contract testing services. The TruDiSC platform vertically integrates:
1. High-efficiency, large-scale hiPSC differentiation technology,
2. Precision cryopreservation technology ensuring post-thaw functional integrity, and
3. Serum-free, regulatory-compliant drug evaluation methodologies to guarantee full quality consistency and superior clinical predictability.
Furthermore, NEXEL is expanding its next-generation Drug Development Tool (DDT) solutions by pairing 2D functional cell and 3D organoid models with AI-driven arrhythmia prediction algorithms. By providing standardized solutions optimized for B2B research environments, NEXEL has positioned itself as a key strategic partner that radically reduces R&D risks, timelines, and costs for global pharmaceutical and biotech companies.
Leveraging proven technology and an expansive global distribution and research network, NEXEL continues to set the new global standard for the non-clinical drug evaluation market.
CONTACT